Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITHAL: Vamifeport in Non-transfusion Dependent Beta-thalassemia
NCT04364269Phase 2Completed
- Sponsor
- CSL Vifor
- Start
- Jun 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of vamifeport in beta thalassemia intermedia (NTDT) (3 arms), sponsored by CSL Vifor. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events at 16 weeks, Changes in Systolic and Diastolic Blood Pressure at 12 weeks and 2 more. Started Jun 2020; status: completed.
02
Drugs
vamifeport
03
Conditions
beta thalassemia intermedia (NTDT)
Beyond the preview
Go deeper on NCT04364269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04364269.